Chronic Lower Respiratory Disease (CLRD) and chronic kidney disease (CKD) are comorbid progressive diseases that have, over the decades, significantly contributed to high mortality rates. The overlapping mechanisms are aggravated by their coexistence, thus resulting in a poorer prognosis. The purpose of the study is to examine countrywide mortality rates related to CLRD and CKD and to identify the disparities among various population groups. The CDC WONDER database was used to discuss age-adjusted mortality rates (AAMRs) of CLRD among patients with chronic kidney disease aged 25 and older, in 1999–2023, by sex and race, by geography, and by metropolitan status. Joinpoint regression was used to calculate Average Annual Percentage Changes (AAPCs) and Annual Percentage Changes (APCs) per 100,000 with 95
A 14-year-old female with juvenile systemic lupus erythematosus (jSLE) presented with a life-threatening and previously unreported triad: the simultaneous onset of acute pancreatitis, severe axonal polyneuropathy, and autoimmune Type 1 Diabetes (T1D). This catastrophic, polysyndromic flare was driven by a hyperinflammatory state consistent with Macrophage Activation Syndrome, with the T1D diagnosis confirmed by high-titer GADA, IA-2A, and ZnT8A autoantibodies. This case provides a rare clinical model of a "perfect storm" in which a systemic inflammatory crisis appears to have inflicted widespread vasculitic injury while simultaneously acting as a "second hit" to trigger a latent, organ-specific autoimmunity. Aggressive immunosuppression with pulse corticosteroids and mycophenolate mofetil led to remission of this multi-fronted immunological attack. This case expands the phenotypic spectrum of jSLE to include a new paradigm of "lupus crisis," demonstrating that a single flare can catastrophically shatter the boundaries between systemic and organ-specific autoimmune diseases. It mandates a high index of suspicion for concurrent, multi-lineage autoimmunity in patients presenting with severe, hyperinflammatory jSLE.
Background: Benign urological lesions in adults are frequently encountered in clinical practice and include renal angiomyolipoma, benign renal masses, and selected symptomatic benign proliferative conditions managed within urology. Although these lesions are non-malignant, they may still cause hemorrhage, pain, obstructive symptoms, diagnostic uncertainty, and treatment-related loss of organ function. Contemporary management has shifted toward more selective intervention and greater emphasis on nephron preservation, but the evidence remains fragmented across lesion types and treatment pathways. Objective: To systematically evaluate current diagnostic approaches and management strategies for benign urological lesions in adults, with emphasis on diagnostic utility, symptom outcomes, complications, lesion progression, recurrence, and preservation of organ function. Methods: A systematic review with qualitative synthesis was conducted in accordance with PRISMA 2020. PubMed/MEDLINE, Scopus, Cochrane CENTRAL, and Web of Science were searched for studies published between January 2014 and March 2024. Eligible studies included adults with radiologically characterized or histologically confirmed benign urological lesions and reported diagnostic or management outcomes. Two reviewers independently screened studies, extracted data, and assessed methodological quality using RoB 2 for randomized trials and the Newcastle-Ottawa Scale for observational studies. Owing to substantial clinical and methodological heterogeneity, findings were synthesized narratively. Results: Eight studies involving 1,427 adults were included. Five studies evaluated renal angiomyolipoma, two examined benign small renal masses, and one assessed symptomatic benign prostatic proliferative disease. Active surveillance was safe for most small asymptomatic angiomyolipomas, with 94% showing no clinically meaningful growth over 36 months in one prospective cohort and 60% of tuberous sclerosis complex-associated cases remaining intervention-free over 5 years. For larger or symptomatic angiomyolipomas, selective arterial embolization preserved renal function better than partial nephrectomy, with a smaller decline in estimated glomerular filtration rate at 12 months (-3.2 vs -11.5 mL/min/1.73 m²; p<0.01), although post-embolization syndrome was more frequent. Percutaneous biopsy for indeterminate small renal masses showed 88% sensitivity, 100% specificity, and a 15% non-diagnostic rate. Conclusion: Current evidence supports surveillance for selected small asymptomatic renal angiomyolipomas and selective arterial embolization as an effective kidney-preserving option for larger or symptomatic lesions. However, the evidence base is predominantly observational and heavily renal-focused, underscoring the need for higher-quality prospective comparative studies across the broader spectrum of benign urological lesions.
BACKGROUND : Cardiac arrest and cardiac arrhythmias are potentially lethal heart conditions the symptoms of which are exacerbated by hyperkalemia. This study evaluates mortality trends of hyperkalemia related cardiac arrest and cardiac arrhythmia deaths in the United States from 1999 to 2020 using CDC WONDER data. METHODS : CDC WONDER Multiple Cause of Death database was used to get data for adults aged 25 and older. ICD-10 code Hyperkalemia was identified using ICD-10 code E87.5. Cardiac arrest and cardiac arrhythmias were identified using ICD-10 codes I46–I49, including I46.0, I46.1, I46.9 ,I47.0, I47.1, I47.2, I47.9,I48 and I49.0–I49.5, I49.8, I49.9 ).AAMRs per 100,000 were stratified by sex, race and ethnicity, region, state and urbanization level. A p value < 0.05 was considered statistically significant. RESULTS : A total of 53,399 deaths were recorded among individuals aged ≥25 years in which the majority of these deaths occurred in medical facilities (85.91%). Overall mortality rate decreased from 1999 (1.13) to 2011 (1.01) followed by rapid increase (1.64) in 2020. AAMRs were consistently higher in males than females throughout the study period (males: 1.34 vs. females: 0.96).Mortality varied by race and ethnicity and geographical region and urbanization with the highest overall AAMR observed among Black or African American individuals followed by Hispanics.Highest mortality was observed in the West, Rhode Island(1.97) and non metropolitan areas CONCLUSION Hyperkalemia-related cardiac arrhythmias and cardiac arrest deaths showed temporal variation from 1999 to 2020. . These findings highlight the need for effective potassium serum level management, and improved access to timely care.
INTRODUCTION:Aortic stenosis is a prevalent and serious heart valve disorder, particularly affecting older adults. A significant subset of these patients presents with small aortic annuli (SAA), complicating the selection of optimal transcatheter aortic valve replacement (TAVR) devices. The comparative efficacy and safety of balloon-expandable valves (BEV) vs. self-expandable valves (SEV) for this subgroup remain uncertain. PURPOSE:This systematic review and meta-analysis aimed to evaluate and compare the clinical and hemodynamic outcomes of BEV and SEV in patients with SAA undergoing TAVR, using the GRADE approach to assess the certainty of evidence. METHODS:A comprehensive electronic search was conducted in PubMed, Embase, Scopus, and other databases up to July 2025. Studies were included if they compared BEV and SEV in patients with SAA. Data extraction and quality assessment followed the Cochrane and PRISMA guidelines. The primary outcomes were new permanent pacemaker implantation and paravalvular leak greater than mild. Secondary outcomes included indexed effective orifice area, mean transvalvular gradient, and prosthesis-patient mismatch (PPM). Random-effects meta-analyses were performed to pool odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs). RESULTS:Fourteen studies comprising 8451 patients (4797 BEV, 3654 SEV) met the inclusion criteria. There was no significant difference in the risk of severe PPM (OR = 0.61, 95% CI: 0.27-1.37, P = 0.23) or moderate/severe PPM (OR = 0.78, 95% CI: 0.45-1.38, P = 0.40) between BEV and SEV. The mean indexed orifice area did not differ significantly (MD = -0.01, 95% CI: -0.12-0.11, P = 0.93). The risk of new permanent pacemaker implantation was similar between groups (OR = 1.03, 95% CI: 0.67-1.59, P = 0.89). BEV were associated with a near-significant increase in moderate or greater paravalvular leak (OR = 1.39, 95% CI: 1.00-1.93, P = 0.05). Mean transvalvular gradients showed no significant difference (MD = -0.91 mmHg, 95% CI: -3.38-1.57, P = 0.47), though SEV showed a trend toward lower gradients. The certainty of evidence was rated as moderate across most outcomes. CONCLUSION:In patients with SAA undergoing TAVR, BEV and SEV yield comparable rates of PPM and permanent pacemaker implantation. However, BEV may be associated with a higher risk of moderate or greater paravalvular leak. Valve selection should be individualized, considering patient anatomy and device-specific characteristics to optimize outcomes.
